Methocarbamol: Difference between revisions
| [unchecked revision] | [checked revision] |
MDElliottMD (talk | contribs) Auto-created stub |
MDElliottMD (talk | contribs) parser-claude: Methocarbamol MedTemplate refill, Top 300 stub upgrade |
||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{MedTemplate | {{MedTemplate | ||
| generic = Methocarbamol | | generic = Methocarbamol | ||
| brand = Robaxin | | brand = Robaxin (oral, injectable) | ||
| classes = | | structure = | ||
| mechanism = | | classes = [[:Category:Skeletal muscle relaxants|Skeletal muscle relaxant (centrally-acting)]] | ||
| uses = <vote slug="acute-muscle-spasm-use">Short-term relief of muscle spasm from acute musculoskeletal conditions (FDA)</vote>, <vote slug="tetanus-adjunct-use">Tetanus adjunct (FDA, IV; rarely needed in current practice with immunization coverage)</vote> | |||
| starting_dose = Oral: 1500 mg PO QID for 2-3 days (load), then 750-1500 mg QID maintenance. IV/IM: 1000 mg every 8 hours for acute spasm | |||
| preparations = Tablets 500, 750 mg; injection 100 mg/mL | |||
| fda_max = 8 g/day (oral, short-term load); 6 g/day (chronic) | |||
| pill_id = | |||
| routes = Oral, intramuscular, intravenous | |||
| onset = ~30 minutes (oral) | |||
| duration = 4-6 hours | |||
| halflife = 1-2 hours<ref name="robaxin-label">FDA Prescribing Information, Robaxin (methocarbamol), Pfizer/various, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/011011s032lbl.pdf</ref> | |||
| bioavailability = ~100% (oral; near-complete absorption)<ref name="robaxin-label" /> | |||
| pregnancy = Limited human data.{{citation needed}} | |||
| legal = [[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance, distinguishing it from carisoprodol which is Schedule IV<ref name="robaxin-label" /> | |||
| mechanism = <vote slug="methocarbamol-mech-claim">Centrally-acting skeletal muscle relaxant with mechanism not fully elucidated; effects appear mediated through general central nervous system depression rather than direct muscle relaxation or specific receptor activity. The lack of receptor-specific action explains both the relatively mild side-effect profile and the variable efficacy across patients.</vote> May cause harmless '''brown, black, blue, or green urine discoloration''' (the classic counseling point). Not associated with the abuse-liability concerns of carisoprodol or the anticholinergic burden of cyclobenzaprine, making methocarbamol a reasonable choice in elderly patients<ref name="robaxin-label" />. | |||
}} | }} | ||
== References == | |||
<references /> | |||
[[Category:Skeletal muscle relaxants]] | |||
Latest revision as of 07:02, 23 May 2026
Methocarbamol
Robaxin (oral, injectable)
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Pharmacy
Starting dose
Oral: 1500 mg PO QID for 2-3 days (load), then 750-1500 mg QID maintenance. IV/IM: 1000 mg every 8 hours for acute spasm
Preparations
Tablets 500, 750 mg; injection 100 mg/mL
US FDA Max
8 g/day (oral, short-term load); 6 g/day (chronic)
Pharmacology
Routes
Oral, intramuscular, intravenous
Onset
~30 minutes (oral)
Duration
4-6 hours
Half-life
1-2 hours[1]
Bioavailability
~100% (oral; near-complete absorption)[1]
Pregnancy
Limited human data.[citation needed]
Legal status
Purported mechanism
Centrally-acting skeletal muscle relaxant with mechanism not fully elucidated; effects appear mediated through general central nervous system depression rather than direct muscle relaxation or specific receptor activity. The lack of receptor-specific action explains both the relatively mild side-effect profile and the variable efficacy across patients.0 May cause harmless brown, black, blue, or green urine discoloration (the classic counseling point). Not associated with the abuse-liability concerns of carisoprodol or the anticholinergic burden of cyclobenzaprine, making methocarbamol a reasonable choice in elderly patients[1].
References
- ↑ 1.0 1.1 1.2 1.3 FDA Prescribing Information, Robaxin (methocarbamol), Pfizer/various, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/011011s032lbl.pdf